Exploring the mechanism of action of glaucocalyxin D against acute myeloid leukemia using network pharmacology, molecular docking and cellular experiments
Open Access
- 27 April 2026
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (6) , 1-15
Abstract
Glaucocalyxin D (GLD), an ent‑kaurane diterpenoid isolated from Isodon species, exhibits extensive pharmacological potential; however, its mechanism of action against acute myeloid leukemia (AML) remains to be elucidated. The present study employed a combined network pharmacology and experimental approach to elucidate the anti‑AML mechanisms of GLD. Potential targets were identified using database mining and a protein‑protein interaction network was constructed. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses highlighted the JAK‑STAT signaling pathway as central to action by GLD. Molecular docking predicted stable binding of GLD to core targets, including STAT3. Experimental validation in HEL and K562 AML cells demonstrated that GLD potently and dose‑dependently inhibits cell proliferation, with efficacy similar to the standard chemotherapeutic agent doxorubicin. Mechanistically, GLD suppressed the phosphorylation of JAK2 and STAT3. GLD also induced mitochondrial apoptosis by modulating the Bcl‑2/Bax ratio and triggered G2/M phase arrest by downregulating cyclin B1 and CDK1. These findings delineated a coherent mechanism whereby GLD exerts anti‑leukemic effects by inhibiting the JAK‑STAT pathway, supporting its potential as a novel lead compound for AML therapy in the future.Keywords
This publication has 33 references indexed in Scilit:
- Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formulaJournal of Ethnopharmacology, 2023
- Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemiaDrug Resistance Updates, 2020
- Glaucocalyxin A alleviates LPS-mediated septic shock and inflammation via inhibiting NLRP3 inflammasome activationInternational Immunopharmacology, 2020
- Cancer and myeloid clonal evolution in the short telomere syndromesCurrent Opinion in Genetics & Development, 2020
- Photodynamic therapy for cancer: Role of natural productsPhotodiagnosis and Photodynamic Therapy, 2019
- Erratum to: JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future ProspectsDrugs, 2017
- Diagnostic work‐up of acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Strategies and Approaches of Targeting STAT3 for Cancer TreatmentACS Chemical Biology, 2016
- Discovery and resupply of pharmacologically active plant-derived natural products: A reviewBiotechnology Advances, 2015
- Anti-inflammatory effects of glaucocalyxin B in microglia cellsJournal of Pharmacological Sciences, 2015